EUROPEAN MEDICINES AGENCY
SCIENCE MEDICINES HEALTH

The European Clinical Trials Regulation

Presented by Dr. Pieter Vankeerberghen, 29.11.2021
CTIS programme manager
Data Analytics and Methods Task Force (TDA), European Medicines Agency

Disclaimer

The presenter does not have any conflict of interests.

The views expressed are those of the presenter.

The Clinical Trial Regulation: *where we come from*

...Before May 2004

National rules, different processes/requirements for authorisation in each EU Member States

...resulted in delays and complications

...Directive 2001/20/EC

(since 1 May 2004)

First step to harmonise processes and requirements for clinical trial authorisations

Introduction of e-application form

...Regulation (EU) No. 536/2014

(published May 2014)

Full harmonisation and combined assessment of multinational trials (after full functionality of the EU portal and EU database)

e-submission

-> Increased transparency

CTR and Clinical trials Information system (CTIS) Benefits

With CTIS sponsors can:



Apply for a clinical trial in up to 30 EU/EEA countries with a **single application:** Single Protocol, Investigators Brochure, IMPD, but per country ICF, …

Facilitate involvement of trial participants by allowing **easy expansion of trials to other EU/EEA countries**

Collaborate across borders for better results and knowledge sharing

Ensure the EU/EEA remains an attractive location for **clinical research investment**

Fulfil all **clinical trial publication requirements** with no additional effort

Why CTR and CTIS?

EUROPEAN MEDICINES AGENCY

CTIS is the business tool of the **Clinical Trials Regulation**.
CTIS **harmonises the submission, assessment and supervision of clinical trials**.

Public health

Facilitates large-scale trials to address key health issues (COVID, EU Beating Cancer plan…)

Research and innovation

Enables knowledge sharing and expert collaboration.

Investment in research

Ensures the EU/EEA remains an attractive clinical research hub globally.

CTR process and timelines

EUROPEAN MEDICINES AGENCY



Part I: Harmonised protocol, single decision by RMS

Part II: Ethics single decision per Member State

Clinical Trials Information System – CTIS - Overview



Clinical Trials Information System - CTIS

EUROPEAN MEDICINES AGENCY

Digitalisation & Improved Efficiency

Increased Transparency

Enhanced Patient Safety

Support to Innovation & Research

- The **single EU entry point** for clinical trial application submissions for sponsors (e-dossier)
  A single application and maintenance process, dossier and timeline; covering clinical trial application to NCA, submission to ethics committee and registration of the clinical trial in a public register; all in one integrated submission
- Harmonised and simplified **end-to-end electronic application procedures** over the life-cycle of clinical trials across the EU
- Collaboration and **coordination in evaluation and supervision of clinical trials** for Member States
- Fully **electronic exchange** of information between sponsors and Member States
- Digital secured **archive** of documents, decisions and information on a clinical trial

Clinical Trials Information System - CTIS

EUROPEAN MEDICINES AGENCY

Digitalisation & Improved Efficiency

Increased Transparency

Enhanced Patient Safety

Support to Innovation & Research

- Offers searchable **clinical trial information** to the patient, the healthcare professional and the general public
- Clinical trial **results available in lay language**
- Information can be retrieved for the life-cycle of a **clinical trial or investigational medicinal product** across trials

Clinical Trials Information System - CTIS

EUROPEAN MEDICINES AGENCY

Digitalisation & Improved Efficiency

Increased Transparency

Enhanced Patient Safety

Support to Innovation & Research

- Patient safety is enhanced in clinical trials as CTIS provides an end-to-end electronic solution for safety reporting of trials
- CTIS facilitates a harmonised assessment in Europe, supported by agreed assessment report templates
- The clinical trial module of EudraVigilance is updated for the electronic reporting of SUSARs by sponsors and re-routing to Member States
- CTIS provides for one single decision per Member State Concerned
- CTIS delivers an electronic Annual safety reports (ASRs) repository

Clinical Trials Information System - CTIS

EUROPEAN MEDICINES AGENCY

Digitalisation & Improved Efficiency

Increased Transparency

Enhanced Patient Safety

Support to Innovation & Research

- CTIS is a unique intuitive tool that facilitates submission of clinical trial applications including those for trials across borders and for investigation of rare diseases. It thereby also supports academic innovative work.
- CTIS offers structured data to allow efficient reporting for scientists
- A clinical trial can be extended to more Member States e.g. to enhance recruitment rates without resubmission/reassessment of the clinical trial application. The implemented CTIS timelines can be shortened.

CTIS Go-Live 31 January 2022

EUROPEAN MEDICINES AGENCY

After Go-Live Member States will use CTIS from the start while sponsors can make use of a transition period.

The volume of **publicly available data in CTIS will gradually start to accumulate**.



Introduction to the common sponsor functionalities

CTIS offers these high-level functionalities to sponsors users. These are: Overview of Clinical Trials (search functionality), Notices & alerts, Annual Safety Reporting, Requests for Information and User administration.



A view of the sponsor functionalities in CTIS – Part I

EUROPEAN MEDICINES AGENCY



Legal basis for transparency in the Regulation (EU) No 536/2014

EUROPEAN MEDICINES AGENCY

The Regulation outlines the requirements for transparency in CTIS

Article 81(4):

4. The EU database shall be publicly accessible unless, for all or part of the data and information contained therein, confidentiality is justified on any of the following grounds:

*(a) protecting **personal data** in accordance with Regulation (EC) No 45/2001;*

*(b) protecting **commercially confidential information**, in particular through taking into account the status of the marketing authorisation for the medicinal product, unless there is an overriding public interest in disclosure;*

*(c) protecting **confidential communication** between Member States in relation to the preparation of the assessment report;*

*(d) ensuring **effective supervision** of the conduct of a clinical trial by Member States*

CTIS – Publication Aspects

- Data and documents of an application that is ‘under evaluation’ will not be made public, unless there is an overriding public interest;
- Only applications on which a **decision** has been reached will be made public;
- All data and documents in the system will be made public with some exceptions;
- The default is always to make public at the first opportunity, e.g. time of decision;
- Sponsors have options to defer the timing of publication of specific data/documents via the deferral mechanism
- Deferral will be part of CTA submission and, therefore, subject to the approval of the Member States Concerned

CTIS –public search for data

The data in CTIS will accumulate over time as sponsors submit their applications and results.
There is a basic search on free text and an advanced search with more options



Basic search - Free text fields; key words

What will not be made public

- Quality related information that include:
  - ❑ The IMPD quality
  - ❑ Scientific advice on quality
  - ❑ Quality related request of information (RFI) raised during the assessment
  - ❑ Quality Assessment reports (draft and final)
- Drafts of assessment reports;
- Versions of documents that are 'not for publication', which may include personal information identifying Member States experts, sponsor staff, MAH/applicant staff, as needed;
- Financial agreements between the sponsor and the investigator site;
- Any requests for information from MS to the sponsor and responses recorded outside of an assessment of an application

Thank you for your attention

Official address Domenico Scarlattilaan 6 ● 1083 HS Amsterdam ● The Netherlands
Telephone +31 (0)88 781 6000
Send us a question Go to www.ema.europa.eu/contact

Follow us on **@EMA_News**